Novo Nordisk's Long Game: AI Partnerships, Pill Competition, and a Market Demanding Faster Answers

Novo Nordisk expands obesity pipeline with oral drugs, combo therapies, and AI partnerships amid rising competition from Eli Lilly's UK-approved oral treatment.

The obesity drug arena is no longer a two-horse race — or so Novo Nordisk's leadership insists. When CEO Mike Doustdar declared on August 13 that the weight-loss market would not crown a single winner, he was framing a strategy that investors have grown increasingly impatient with. The tension between that long-term vision and the market's demand for near-term results now defines the stock's trajectory.

That positioning took on added significance just two days later, when Eli Lilly secured UK approval for its oral obesity treatment Foundayo — the second oral GLP-1 authorization in Britain, following Novo's own Wegovy pill in June. The timing underscored how quickly the competitive landscape is shifting, particularly in the oral segment where analysts see the most vulnerability.

Building a Broader Defense

Novo's response has been to widen its pipeline rather than double down on a single candidate. The company is pursuing multiple fronts simultaneously: the Wegovy pill, the combination therapy CagriSema, and most recently OASIS-5, a late-stage trial launched August 12 that will test whether lower maintenance doses of the Wegovy pill can maintain efficacy. That study, enrolling 450 adults, is expected to run until 2028 — a timeline that stretches far beyond what most investors are willing to price in today.

The company is also hedging its bets beyond the GLP-1 class itself. A partnership with biotech firm Novonesis is exploring microbiome-based supplements that could complement existing obesity treatments, though results from that collaboration aren't expected until the second half of 2027. Both initiatives represent bets on the future rather than remedies for the current competitive pressure.

Meanwhile, Novo has moved to strengthen its technological infrastructure. The company is expanding its collaboration with Amazon Web Services, establishing a co-innovation hub in London where researchers from both organizations will use artificial intelligence to accelerate drug discovery. The initiative is part of a broader effort to diversify beyond the weight-loss franchise that has driven the company's recent fortunes.

Legal Wins and Capital Returns

On the legal front, Novo secured a favorable ruling in early August when a Dutch court issued an injunction against an unapproved compounded semaglutide nasal spray — a decision that protects patients from an unauthorized imitation product. Such cases have multiplied as the success of GLP-1 treatments has attracted a wave of copycat manufacturers.

The company has also continued its capital return program, extending its share buyback through August. The stock traded ex-dividend on August 14, with shareholders entitled to a payout of 3.75 Danish kroner per share. Regulatory filings under the EU Market Abuse Regulation also disclosed share transactions by board members and executives, including vesting-related allocations to Executive Vice President Emil Kongshøj Larsen.

The Analyst Divide

The market's ambivalence is reflected in the analyst community. Berenberg downgraded Novo to Hold on August 12, cutting its price target to $47, with the rationale pointing squarely at competition in the oral pill market. That skepticism stands in contrast to the company's operational performance: Novo raised its full-year guidance in early August following a stronger-than-expected start to the year, and the stock has since recovered 4.1 percent from its post-guidance levels.

Yet the numbers tell a more complicated story. The shares closed Friday at €39.98, up 1.0 percent on the day and 2.9 percent for the week, but still trailing the 50-day average of €41.58. The stock sits roughly 27 percent below its 52-week high of €54.86, reached in January. Technical indicators offer little clarity: the RSI of 45.3 suggests neither overbought nor oversold conditions, while the 30-day annualized volatility of 40 percent points to a market struggling to reach a consensus.

A Market Short on Patience

The fundamental question is whether Novo's breadth-first strategy can deliver results before the competitive window closes. The company's operational strength is not in dispute — the guidance raise and dividend payout attest to that. But with OASIS-5 and the Novonesis partnership requiring years rather than months to produce meaningful data, the market's patience is being tested.

Doustdar's assertion that no single player will dominate the obesity market may prove strategically sound. For shareholders, however, it translates into a waiting game — and right now, the market appears to have little appetite for it.